South Clin Ist Euras. 2019; 30(3): 266-271 | DOI: 10.14744/scie.2019.05924

Metabolic Syndrome in Patients with Schizophrenia and Bipolar Disorder in a Community Mental Health Center

Kader Semra Karatas¹, Bulent Bahceci¹, Hediye Aktürk², Feride Alakuþ^3
1Department of Psychiatry, Recep Tayyip Erdoðan University Faculty of Medicine, Rize, Turkey
²Department of Psychiatry, Rize State Hospital, Rize, Turkey
³Department of Internal Medicine, Rize State Hospital, Rize, Turkey

INTRODUCTION: The aim of this study was to determine the frequency of metabolic syndrome (MetS) in patients with schizophrenia and bipolar disorder (BD) receiving antipsychotic (AP) medications.
METHODS: A total of 207 patients with schizophrenia and BD, diagnosed according to the DSM-IV criteria and receiving a regular AP treatment, were followed up in the Community Mental Health Center. The MetS was diagnosed according to the diagnostic criteria of the International Diabetes Federation. Patients with MetS were compared to those without it in terms of sociodemographic and clinical characteristics, as well as the AP medications administered.
RESULTS: MetS was detected in 28.5% of patients. The most commonly identified clinical finding was a large waist circumference (61%). Of the clinical characteristics among the patients using AP, a large waist circumference and high blood glucose levels were found to be significantly different. MetS was found to be more common in patients with schizophrenia on AP who used the clozapine monotherapy (18.6%), and in patients with BD who used quetiapine (11.9%). Valproate was found to be more commonly used in patients with BD in whom MetS was detected.
DISCUSSION AND CONCLUSION: A large waist circumference and high blood glucose levels are the most important follow-up criteria.

Keywords: Antipsychotic medications, bipolar disorder, clinical characteristics;metabolic syndrome;schizophrenia.

---

Toplum Ruh Saðlýðý Merkezinde Takip Edilen Þizofreni ve Ýki Uçlu Bozukluk Hastalarýnda Metabolik Sendrom

Kader Semra Karatas¹, Bulent Bahceci¹, Hediye Aktürk², Feride Alakuþ^3
1Recep Tayyip Erdoðan Üniversitesi / Týp Fakültesi / Psikiyatri Anabilim Dalý / Rize / Türkiye
²Rize Devlet Hastanesi / Psikiyatri Bölümü / Rize / Türkiye
³Rize Devlet Hastanesi / Dahiliye Bölümü / Rize / Türkiye

GÝRÝÞ ve AMAÇ: Bu çalýþmada, antipsikotik ilaçlarla tedavi altýnda olan þizofreni ve iki uçlu bozukluk (ÝUB) hastalarýnda metabolik sendrom (MetS) sýklýðýnýn saptanmasý amaçlanmýþtýr.
YÖNTEM ve GEREÇLER: DSM-IV taný kriterlerine göre tanýsý konan, Toplum Ruh Saðlýðý Merkezi’nde takip edilen, düzenli antipsikotik tedavi alan 207 þizofreni ve ÝUB hastalarý çalýþmaya alýndý. MetS tanýsý Uluslararasý Diyabet Fedarasyonu taný kriterlerine göre kondu. MetS tanýsý konan hasta gruplarý arasýnda sosyodemografik, klinik özellikler ve uygulanan antipsikotik ilaçlar açýsýndan karþýlaþtýrma yapýldý.
BULGULAR: Hastalarýn %28.5’inde MetS saptandý. En sýk saptanan klinik bulgu, bel çevresi geniþliði (%61) idi. Antipsikotik kullanan hastalarda klinik özellikler arasýnda bel çevresi geniþliði ve kan glukoz seviyesi yüksekliði anlamlý olarak farklý bulundu. Antipsikotik kullanan þizofreni hastalarýnda monoterapilerde klozapin (%18.6), ÝUB hastalarýnda ketiyapin (%11.9) kullanýmýnda MetS daha sýk olarak bulundu. MetS saptanan ÝUB hastalarýnda duygudurum düzenleyici ilaç olarak valproatýn daha sýk kullanýldýðý saptandý.
TARTIÞMA ve SONUÇ: Bel çevresi geniþliði ve kan þekeri yüksekliði takipte en önemli kriterlerdir.

Anahtar Kelimeler: Antipsikotik ilaçlar, ikiuçlu bozukluk; klinik özellikler; metabolik sendrom; þizofreni.

---

CITE